Cabozantinib and prostate cancer: Inhibiting seed and disrupting soil?

Abstract

Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil. © 2014 American Association for Cancer Research.